Abstract

News ArticleThe Food and Drug Administration on April 6 approved vandetanib for the treatment of metastatic medullary thyroid cancer in adults - making it the first drug approved for this rare cancer.Vandetanib is indicated for adults with metastatic medullary thyroid cancer, "who are ineligible for surgery and who have disease that is growing or causing symptoms," the agency said. It is administered orally once a day.Approval was based on an international phase III study that compared treatment...